Molecular Partners AG downgraded by Credit Suisse
$MOLN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Credit Suisse downgraded Molecular Partners AG from Neutral to Underperform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/30/2022 | Outperform → Sector Perform | RBC Capital Mkts | |
| 8/29/2022 | $30.00 → $8.00 | Outperform → Mkt Perform | SVB Leerink |
| 5/25/2022 | Underperform → Neutral | Credit Suisse | |
| 4/27/2022 | Neutral → Underperform | Credit Suisse |
RBC Capital Mkts downgraded Molecular Partners AG from Outperform to Sector Perform
SVB Leerink downgraded Molecular Partners AG from Outperform to Mkt Perform and set a new price target of $8.00 from $30.00 previously
Credit Suisse upgraded Molecular Partners AG from Underperform to Neutral
SC 13D/A - MOLECULAR PARTNERS AG (0001745114) (Subject)
SC 13D - MOLECULAR PARTNERS AG (0001745114) (Subject)
SC 13G/A - MOLECULAR PARTNERS AG (0001745114) (Subject)
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that it will issue its fourth quarter and full year financial results for 2023 on March 14, which will be followed by a conference call the next day to discuss the results. Molecular Partners' Chief Executive Officer Patrick Amstutz will also present at the 44th Annual Cowen Health Care Conference taking place in Boston, MA, and will participate in the Leerink Global Biopharma Conference taking place in Miami, FL along with oth
Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023 Positive MP0317 data of ongoing Phase 1 clinical trial presented at ASCO confirm proposed MOA and indicates favorable safety profile in patients with advanced solid tumors, supporting future combination studies with potential partners; presently finalizing recruitment of weekly dosing regimen Preclinical data supporting the Radio DARPin Therapy platform presented at leading conferences TAT12, AACR and SNMMI in H1 2023 Funded well into 2026 with cash of CHF 218 million as of June 30
Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)Presented preclinical data supporting the unique design and mechanism of MP0533 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionEstablished Radio DARPin Therapy (RDT) Platform, formally selecting tumor-associated protein Delta-like ligand 3 (DLL3) as a first targetPresented interim safety and mechanism data from ongoing Phase 1 study of MP0317 for the treatment of solid tumors at the 37th Society for Immunotherapy of Cancer (SITC) Annual MeetingSigned in early Janu
New agreement enables both companies to fuel a broad and innovative pipeline of 212Pb-Radio-DARPin candidates, bringing the total number of programs up to tenExpanded partnership highlights the parties' emerging leadership in targeted alpha therapies (TAT), leveraging Orano Med's expertise in the development of 212Pb-based TAT and vast proprietary supply of 212Pb and Molecular Partners' unique Radio-DARPins as an ideal vector for radiopharmaceuticalsMost advanced 212Pb-Radio-DARPin, DLL3-targeted MP0712, starts clinical trials in 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., and PARIS, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR – Molecular Partn
Radio-DARPin MP0712 against DLL3, in co-development with Orano Med, to enter first-in-human study in 2025Mesothelin named as second target in Radio-DARPin pipeline, program to be co-developed with Orano MedOrano Med partnership on Radio-DARPins now expanded to 10 programsMP0533 clinical data show improved response rate and depth in cohort 8 with steeper step-up and more frequent dosing; additional dose densification planned in cohort 9, updates expected in 2025CD3 Switch-DARPin research proof-of-concept of conditional T cell activation and CD2 co-stimulation shown in solid tumors, further data in Q2 2025 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 12, 2025 (GLOBE NEWSWIRE) -- A
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced it will attend and present the Company's latest developments and outlook for 2025 at two upcoming investor conferences in January. Baader Helvea Swiss Equities Conference, taking place January 8-10 in Bad Ragaz, Switzerland Chief Operating Officer Alexander Zürcher to present on Wednesday, January 8 at the Grand Resort Bad Ragaz. 43rd Annual JP Morgan Healthcare Conference, January 13-16
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)
6-K - MOLECULAR PARTNERS AG (0001745114) (Filer)